Safety and Tolerability of ZE74-0282 in Healthy Volunteers

A Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of ZE74-0282 in Healthy Volunteers

This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in healthy adult volunteers.

Study Overview

• Status: Recruiting
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: ZE74-0282-0001 or placebo

Detailed Description

This is a double-blind, randomized, placebo-controlled, first-in-human Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of ZE74-0282 in healthy adult volunteers. A total of up to 64 participants are planned: 48 participants in Part A and 16 participants in Part B. Each cohort will enroll 8 participants, with 6 randomized to ZE74-0282 and 2 randomized to matching placebo. Dose levels and cohort progression will be reviewed sequentially by the Safety Review Committee based on blinded safety and available pharmacokinetic data.

Part A comprises Cohorts 1, 2, 2a, 3, 4, and 5. It evaluates single ascending doses and, where selected by the Safety Review Committee, split or twice-daily dosing on Day 1. Cohort 2a evaluates 75 mg twice daily, administered 12 hours (+/- 30 minutes) apart on Day 1, for a total daily dose of 150 mg. Dosing in each Part A cohort begins with 2 sentinel participants before dosing the remaining participants. Part A participants are confined from Day -1 through Day 4 and complete the end-of-study visit on Day 8 (+/- 1 day).

Part B comprises Cohorts 6 and 7 and evaluates multiple ascending doses for 7 days. Cohort 6 receives 75 mg twice daily and Cohort 7 receives 150 mg twice daily. Doses are administered approximately 12 hours (+/- 30 minutes) apart on Days 1 through 6, with a morning dose only on Day 7, for a total of 13 doses. Part B participants are confined from Day -1 through Day 8, have a follow-up telephone call on Day 11, and complete the end-of-study visit on Day 18 (+/- 1 day).

• Study Type: Interventional
• Enrollment (Estimated): 64
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Ekaterina Dokukina; Phone Number: +1 858 353 4108; Email: kdokukina@eilenther.com

Study Locations

• Australia
  • New South Wales
    • Randwick, New South Wales, Australia, 2031
      • Recruiting
      • Scientia Clinical Research Ltd.
      • Contact: Christopher Argent, Dr.; Phone Number: 02 9382 5844; Email: christopher.argent@scientiaclinicalresearch.com.au

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy volunteers will be included in the study if they satisfy all of the following criteria:

  1. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
  2. Adult males and females, 18 to 55 years of age (inclusive) at Screening.
  3. Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2, with a body weight ≤100 kg at Screening.

  4. Medically healthy (in the opinion of the PI or delegate), as determined by pre-study medical history, and without CS abnormalities including the following:

     1. Physical examination without any clinically relevant findings;
     2. Systolic blood pressure in the range of 90 to 160 mmHg and diastolic blood pressure in the range of 50 to 95 mmHg after resting for 5 minutes in a semi-supine or supine position.
     3. Pulse rate in the range of 45 to 100 beats per minute after 5 minutes resting in a semi-supine or supine position.
     4. Body temperature (tympanic), between 35.5°C and 37.7°C.
     5. Electrocardiogram without CS abnormalities including QTcF <450 msec.

  5. Female volunteers:

     1. Must be of non childbearing potential i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the screening visit or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle stimulating hormone [FSH] level consistent with postmenopausal status, per local laboratory guidelines), or
     2. If of childbearing potential, must:

     i. Have a negative pregnancy test at the screening visit and on admission to the study site on Day -1.

     ii. Agree not to attempt to become pregnant or donate ova from signing the ICF until at least 30 days after the last dose of study drug.

     iii. Agree to use adequate contraception (defined as use of a condom by the male partner combined with use of a highly effective method of contraception [Section 10.4.3]) from the time of consent/screening until at least 30 days after the last dose of study drug, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.

  6. Male volunteers:

     1. Must agree not to donate sperm from signing the ICF until at least 90 days after the last dose of study drug.
     2. If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception (defined as use of a condom combined with use of a highly effective method of contraception) from signing the ICF until at least 90 days after the last dose of study drug.
     3. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, must agree to use a condom from signing the ICF until at least 5 days after the last dose of study drug.
  7. Have suitable venous access for blood sampling.
  8. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion Criteria:

• Healthy volunteers will be excluded from the study if there is evidence of any of the following at the screening visit or prior to dosing at the timepoint in the SoA:

  1. History of anaphylaxis or other significant allergy which, in the opinion of the PI (or delegate), would interfere with the volunteer's ability to participate in the study.
  2. History or presence of CS cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease/disorder, including any acute illness, within the past 3 months determined by the PI (or delegate) to be clinically relevant.
  3. History of surgery or hospitalisation within 3 months prior to screening, or surgery planned during the study.
  4. Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma with histopathologically-confirmed clear margins).
  5. Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.
  6. History of risk factors for torsade de pointes (including a family history of long QT syndrome or sudden cardiac death) or a known arrythmia.
  7. Presence or having sequelae of gastrointestinal, liver (including Gilbert's syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  8. Liver function test results elevated more than 1.5 fold above the ULN for gamma glutamyl transferase, bilirubin (total, conjugated and unconjugated), ALP, AST or ALT. Volunteers with ALP and/or ALT/AST above the limits specified may be included, at the discretion of the PI (or delegate), if the levels are unaccompanied by clinical signs and are determined to be normal variants.
  9. Estimated creatinine clearance <60 mL/min using the Cockcroft-Gault formula or serum creatinine >1.5 fold above the ULN.
  10. A history of or positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies at the screening visit.
  11. Positive drugs of abuse test or alcohol breath test results at the screening visit and/or on admission to the study site on Day 1. Note that positive carbon monoxide test at Screening is not exclusionary.
  12. Regular consumption of more than 10 standard alcoholic drinks/week and/or more than 4 standard alcoholic drinks on any one day, where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc/Vol], 100 mL wine [12% Alc/Vol], or 30 mL spirit [40% Alc/Vol]).
  13. Participants must be nonsmokers (including tobacco, nicotine replacement therapy, e-cigarettes and marijuana) for at least 3 months prior to the dose of study drug, have a negative carbon monoxide test at Screening and check-in (Day -1) to the clinical facility and refrain from smoking for the duration of the study. Note that positive carbon monoxide test at Screening is not exclusionary.
  14. Females who are breastfeeding or are planning to breastfeed from screening until 3 months after the dose of study drug (or 5 × half-lives, whichever is longer).
  15. Unable to swallow oral medication
  16. Use of any prescription or over-the-counter medication (including oral contraceptives herbal products, nutritional supplements, diet aids, vitamin supplements, minerals and hormone supplements) within 7 days or 5 half-lives of the medication (whichever is longer) prior to the dose of study drug, except the use of paracetamol doses of 500 mg up to every 6 hours or 2 g per day maximum for no more than 3 consecutive days in one week.
  17. Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medication within 10 days prior to dose of study drug.
  18. Use of inactivated vaccines within 14 days or live vaccines within 30 days prior to the study drug administration and during the study.
  19. Participants must not take systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) within 28 days or 5 half-lives of any relevant agent(s) (whichever is longer) prior to dosing and during the study.
  20. Donation of blood or plasma within 30 days prior to dosing of study drug, or loss of whole blood of more than 500 mL within 30 days prior to first dose of study drug, or receipt of a blood transfusion within 1 year of the first dose of study drug.
  21. Participation in a clinical study of an investigational drug or investigational device within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to screening.
  22. Any other condition or prior therapy that in the opinion of the PI (or delegate) would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part A - Cohort 1: 75 mg single dose; Eight participants will be randomized 3:1: 6 participants to a single oral 75 mg dose of ZE74-0282 and 2 participants to matching placebo on Day 1 under fasted conditions.	Drug: ZE74-0282-0001 or placebo; The participant will receive ZE74-0282-0001 or placebo
Experimental: Part A - Cohort 2: nominal 150 mg single dose; Eight participants will be randomized 3:1: 6 participants to the Safety Review Committee-confirmed oral ZE74-0282 dose (nominally 150 mg) and 2 participants to matching placebo on Day 1. Fasted or fed conditions will be selected based on Safety Review Committee review.	Drug: ZE74-0282-0001 or placebo; The participant will receive ZE74-0282-0001 or placebo
Experimental: Part A - Cohort 2a: 75 mg BID split dose; Eight participants will be randomized 3:1: 6 participants to ZE74-0282 and 2 participants to matching placebo. Two oral doses will be administered on Day 1: 75 mg at Hour 0 and 75 mg 12 hours (+/- 30 minutes) later, for a total daily dose of 150 mg.	Drug: ZE74-0282-0001 or placebo; The participant will receive ZE74-0282-0001 or placebo
Experimental: Part A - Cohort 3: nominal 225 mg; Eight participants will be randomized 3:1: 6 participants to ZE74-0282 and 2 participants to matching placebo. The Safety Review Committee will confirm the dose and whether it is administered once or as divided twice-daily doses on Day 1, and whether dosing is under fasted or fed conditions. The nominal dose level is 225 mg.	Drug: ZE74-0282-0001 or placebo; The participant will receive ZE74-0282-0001 or placebo
Experimental: Part A - Cohort 4: nominal 300 mg; Eight participants will be randomized 3:1: 6 participants to ZE74-0282 and 2 participants to matching placebo. The Safety Review Committee will confirm the dose and whether it is administered once or as divided twice-daily doses on Day 1, and whether dosing is under fasted or fed conditions. The nominal dose level is 300 mg.	Drug: ZE74-0282-0001 or placebo; The participant will receive ZE74-0282-0001 or placebo
Experimental: Part A - Cohort 5: nominal 375 mg; Eight participants will be randomized 3:1: 6 participants to ZE74-0282 and 2 participants to matching placebo. The Safety Review Committee will confirm the dose and whether it is administered once or as divided twice-daily doses on Day 1, and whether dosing is under fasted or fed conditions. The nominal dose level is 375 mg.	Drug: ZE74-0282-0001 or placebo; The participant will receive ZE74-0282-0001 or placebo
Experimental: Part B - Cohort 6: 75 mg BID for 7 days; Eight participants will be randomized 3:1: 6 participants to ZE74-0282 and 2 participants to matching placebo. Participants will receive 75 mg twice daily approximately 12 hours (+/- 30 minutes) apart on Days 1 through 6 and one 75 mg morning dose on Day 7, for a total of 13 doses.	Drug: ZE74-0282-0001 or placebo; The participant will receive ZE74-0282-0001 or placebo
Experimental: Part B - Cohort 7: 150 mg BID for 7 days; Eight participants will be randomized 3:1: 6 participants to ZE74-0282 and 2 participants to matching placebo. Participants will receive 150 mg twice daily approximately 12 hours (+/- 30 minutes) apart on Days 1 through 6 and one 150 mg morning dose on Day 7, for a total of 13 doses.	Drug: ZE74-0282-0001 or placebo; The participant will receive ZE74-0282-0001 or placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in haematology parameters	Change from baseline in Haematocrit, Haemoglobin, Mean corpuscular haemoglobin, Mean corpuscular haemoglobin concentration, Mean corpuscular volume, Mean platelet volume, Packed cell volume, Platelet count, Red blood cell count, Reticulocyte count, White blood cell count.	Baseline to Day 8
Change from Baseline in clinical chemistry parameters	Change from baseline in Albumin, Alkaline phosphatase, Alanine aminotransferase, Amylase, Anion gap, Aspartate aminotransferase, Bicarbonate, Calcium, Ionised calcium, Chloride, Conjugated (direct) bilirubin, Creatinine, Creatinine kinase.	Baseline to Day 8
Change from baseline in coagulation parameters	Change from baseline in Activated partial thromboplastin time, Fibrinogen, International normalised ratio/ Prothrombin time	Baseline to Day 8
Change from Baseline in urinalysis parameters	Change from baseline in Bilirubin, Blood, Glucose, Ketones, Leukocyte esterase, Nitrite, pH, Protein, Specific gravity, Urobilinogen.	Baseline to Day 8
Incidence of AEs/SAEs	Number of participants with Adverse Events (AEs), serious Adverse Events (SAEs) (including withdrawals due to AEs)	Baseline to Day 8
Change from Baseline in body weight	A measure of change from Baseline in body weight	Baseline to Day 8
Change from Baseline in blood pressure	A measure of change from Baseline in blood pressure	Baseline to Day 8
Change from Baseline in electrocardiogram (ECG) QT interval	A measure of change from Baseline in ECG QT interval	Baseline to Day 8
Change from Baseline in pulse rate	A measure of change from Baseline in pulse rate	Baseline to Day 8
Change from Baseline in respiratory rate	A measure of change from Baseline in respiratory rate	Baseline to Day 8
Change from Baseline in temperature	A measure of change from Baseline in temperature	Baseline to Day 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum observed plasma concentration	To assess maximum observed plasma concentration	PK samples will be collected from Day 1 to Day 4 and on Day 8
Time to Cmax	To assess time to Cmax	PK samples will be collected from Day 1 to Day 4 and on Day 8
Area under the concentration-time curve from 0 to time of last quantifiable concentration	To assess area under the concentration-time curve from 0 to time of last quantifiable concentration	PK samples will be collected from Day 1 to Day 4 and on Day 8
Area under the concentration-time curve from 0 to 24 hours	To assess area under the concentration-time curve from 0 to 24 hours	PK samples will be collected from Day 1 to Day 4 and on Day 8
Area under the concentration-time curve from 0 to infinity	To assess area under the concentration-time curve from 0 to infinity	PK samples will be collected from Day 1 to Day 4 and on Day 8
Apparent terminal elimination half-life	To assess apparent terminal elimination half-life	PK samples will be collected from Day 1 to Day 4 and on Day 8
Terminal elimination rate constant	To assess terminal elimination rate constant	PK samples will be collected from Day 1 to Day 4 and on Day 8
Total apparent body clearance following oral administration	To assess total apparent body clearance following oral administration	PK samples will be collected from Day 1 to Day 4 and on Day 8
Apparent volume of distribution following oral administration	To assess apparent volume of distribution following oral administration	PK samples will be collected from Day 1 to Day 4 and on Day 8
Trough plasma concentration (Ctrough) - Part B	Plasma concentration immediately before the next scheduled dose during multiple dosing.	Predose on Day 1 through 264 hours after the Day 7 morning dose (Day 18).
Apparent steady-state clearance - Part B	Apparent clearance of ZE74-0282 at steady state following repeated oral administration.	Predose on Day 1 through 264 hours after the Day 7 morning dose (Day 18).
Apparent steady-state volume of distribution (Vss/F) - Part B	Apparent volume of distribution of ZE74-0282 at steady state following repeated oral administration.	Predose on Day 1 through 264 hours after the Day 7 morning dose (Day 18).
Accumulation ratio based on Cmax (RCmax) - Part B	Ratio of Cmax after repeated dosing to Cmax after the first dose.	Predose on Day 1 through 264 hours after the Day 7 morning dose (Day 18).
Accumulation ratio based on AUC0-12 (RAUC) - Part B	Ratio of AUC0-12 after repeated dosing to AUC0-12 after the first dose.	Predose on Day 1 through 264 hours after the Day 7 morning dose (Day 18).

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of trough concentrations after 150 mg single-dose and 75 mg BID split-dose administration	Compare the 24-hour plasma concentration after a single 150 mg dose with the 12-hour plasma concentrations after each 75 mg dose in the split-dose cohort.	Predose through 24 hours after the first dose on Day 1.
Comparison of Cmax and AUC0-24 after 150 mg single-dose and 75 mg BID split-dose administration	Compare Cmax and AUC0-24 between the 150 mg single-dose cohort and the 75 mg twice-daily split-dose cohort.	Predose through 24 hours after the first dose on Day 1.
Exposure after the second versus first 75 mg dose in the split-dose cohort	For Cohort 2a, compare exposure after the second 75 mg dose with exposure after the first 75 mg dose, including an accumulation ratio where data permit.	Part A: Predose through 24 hours after the first dose on Day 1.

Collaborators and Investigators

• Sponsor: Eilean Therapeutics AU Pty Ltd

Study record dates

Study Major Dates

• Study Start (Actual): April 16, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): January 1, 2027

Study Registration Dates

• First Submitted: March 23, 2026
• First Submitted That Met QC Criteria: April 6, 2026
• First Posted (Actual): April 14, 2026

Study Record Updates

• Last Update Posted (Actual): July 28, 2026
• Last Update Submitted That Met QC Criteria: July 25, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: myelofibrosis; chronic myeloid leukemia; essential thrombocytosis; polycythaemia vera
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Chronic Disease; Disease Attributes; Neoplasms by Histologic Type; Hematologic Diseases; Blood Coagulation Disorders; Leukemia, Myeloid; Bone Marrow Diseases; Hemorrhagic Disorders; Leukemia; Blood Platelet Disorders; Myeloproliferative Disorders; Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases; Thrombocytosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Thrombocythemia, Essential; Polycythemia; Primary Myelofibrosis
• Other Study ID Numbers: ZE74-0282-0001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No